NASDAQ : PBM
Psyence Biomedical Ltd. — Financial statements
Healthcare · Biotechnology · Canada
Last price 3.31 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 12.63M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 4.77M | 4.77M | 3.32M | 1.80M | 1.63M | 1.72M |
| Research & Development | 1.47M | 1.47M | 342.17K | 954.59K | 1.61M | 137.24K |
| Operating Expenses | 6.24M | 6.24M | 3.66M | 2.75M | 3.23M | 1.86M |
| Operating Income | -6.24M | -6.24M | -3.66M | -2.75M | -3.23M | -1.86M |
| Interest Expense | -9.52K | -9.52K | -9.27K | -52.94K | ||
| Interest & Investment Income | 263.37K | 263.37K | 95.79K | 2.13K | 1.55K | |
| Earnings From Equity Investments | -45.24K | -45.24K | ||||
| Currency Exchange Gain (Loss) | -1.14K | -1.14K | -7.32K | -2.69K | 26.91K | -2.29K |
| Other Non Operating Income (Expenses) | -1.33M | -1.33M | 509.45K | 573.09K | ||
| EBT Excluding Unusual Items | -7.36M | -7.36M | -3.07M | -2.23M | -3.21M | -1.86M |
| Gain (Loss) on Sale of Investments | 427.00K | 427.00K | 22.97K | |||
| Other Unusual Items | 4.06M | -48.93M | ||||
| Pretax Income | -6.94M | -6.94M | 1.01M | -51.16M | -3.21M | -1.86M |
| Net Income | -6.94M | -6.94M | 1.01M | -51.16M | -3.21M | -1.86M |
| Net Income to Common | -6.94M | -6.94M | 1.01M | -51.16M | -3.21M | -1.86M |
| Shares Outstanding (Basic) | 552.28K | 552.28K | 30.89K | |||
| Shares Outstanding (Diluted) | 552.28K | 552.28K | 30.89K | |||
| EPS (Basic) | -12.56 | -12.56 | 32.76 | |||
| EPS (Diluted) | -12.56 | -12.56 | 32.76 | |||
| Free Cash Flow | -8.14M | -8.14M | -3.74M | -2.95M | -1.59M | -1.40M |
| Free Cash Flow Per Share | -14.74 | -14.74 | -121.22 | |||
| EBITDA | -6.23M | -6.23M | -3.66M | -2.75M | ||
| D&A For EBITDA | 5.27K | 5.27K | 4.27K | 240.00 | ||
| EBIT | -6.24M | -6.24M | -3.66M | -2.75M | -3.23M | -1.86M |
Balance sheet
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 7.44M | 7.44M | 6.14M | 733.19K | 1.33M | 1.76M |
| Cash & Short-Term Investments | 7.44M | 7.44M | 6.14M | 733.19K | 1.33M | 1.76M |
| Other Receivables | 109.78K | 109.78K | 137.35K | 41.75K | 149.37K | 39.55K |
| Receivables | 362.76K | 362.76K | 137.35K | 41.75K | 149.37K | 39.55K |
| Prepaid Expenses | 1.26M | 1.26M | 251.80K | 322.13K | 77.05K | 5.39K |
| Restricted Cash | 47.19K | 47.19K | 35.96K | 29.61K | 29.56K | 32.04K |
| Total Current Assets | 9.11M | 9.11M | 6.56M | 1.13M | 1.59M | 1.83M |
| Property, Plant & Equipment | 6.06K | 6.06K | 11.10K | 5.49K | ||
| Long-Term Investments | 8.06M | 8.06M | 745.00K | |||
| Other Long-Term Assets | 389.76K | 389.76K | ||||
| Total Assets | 17.57M | 17.57M | 7.32M | 1.13M | 1.59M | 1.83M |
| Accounts Payable | 229.51K | 229.51K | 261.94K | 562.35K | 1.63M | 36.89K |
| Accrued Expenses | 84.68K | 84.68K | 50.48K | 125.95K | 162.56K | 94.87K |
| Short-Term Debt | 10.45M | |||||
| Other Current Liabilities | 309.00K | 309.00K | 281.95K | 968.51K | ||
| Total Current Liabilities | 623.19K | 623.19K | 594.37K | 12.10M | 1.79M | 131.76K |
| Total Liabilities | 623.19K | 623.19K | 594.37K | 12.10M | 1.79M | 131.76K |
| Common Stock | 78.75M | 78.75M | 61.75M | 46.13M | 5.93M | 1.70M |
| Retained Earnings | -63.38M | -63.38M | -56.45M | -57.46M | -6.30M | |
| Comprehensive Income & Other | 1.58M | 1.58M | 1.42M | 361.06K | 165.36K | |
| Shareholders' Equity | 16.94M | 16.94M | 6.72M | -10.97M | -200.44K | 1.70M |
| Total Liabilities & Equity | 17.57M | 17.57M | 7.32M | 1.13M | 1.59M | 1.83M |
| Total Debt | 10.45M | |||||
| Net Cash (Debt) | 7.44M | 7.44M | 6.14M | -9.71M | 1.33M | 1.76M |
| Net Cash Per Share | 13.48 | 13.48 | 198.63 | |||
| Filing Date Shares Outstanding | 3.81M | 3.81M | 90.88K | |||
| Total Common Shares Outstanding | 2.29M | 2.29M | 90.88K | |||
| Working Capital | 8.49M | 8.49M | 5.97M | -10.98M | -200.44K | 1.70M |
| Book Value Per Share | 7.39 | 7.39 | 73.96 | |||
| Tangible Book Value | 16.94M | 16.94M | 6.72M | -10.97M | -200.44K | 1.70M |
| Tangible Book Value Per Share | 7.39 | 7.39 | 73.96 | |||
| Machinery | 15.83K | 15.83K | 15.60K | 5.73K |
Cash flow statement
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Net Income | -6.94M | -6.94M | 1.01M | -51.16M | -3.21M | -1.86M |
| Depreciation & Amortization | 5.27K | 5.27K | 4.27K | 240.00 | ||
| Loss (Gain) on Equity Investments | 45.24K | 45.24K | ||||
| Stock-Based Compensation | 155.34K | 155.34K | 317.88K | 221.29K | 332.07K | |
| Other Operating Activities | -196.40K | -196.40K | -4.36M | 49.07M | -84.50K | |
| Change in Accounts Receivable | -225.42K | -225.42K | -95.60K | 107.62K | -109.86K | 100.05K |
| Change in Accounts Payable | 13.44K | 13.44K | -360.93K | -1.04M | 1.66M | 29.56K |
| Change in Other Net Operating Assets | -1.00M | -1.00M | 70.33K | -245.07K | -71.67K | 128.00 |
| Operating Cash Flow | -8.14M | -8.14M | -3.73M | -2.95M | -1.59M | -1.40M |
| Capital Expenditures | -229.00 | -229.00 | -9.88K | -5.73K | ||
| Investment in Securities | -4.50M | -4.50M | ||||
| Other Investing Activities | -11.23K | -11.23K | -6.35K | -32.04K | ||
| Investing Cash Flow | -4.51M | -4.51M | -16.23K | -5.73K | -32.04K | |
| Short-Term Debt Issued | 1.00M | 2.50M | ||||
| Total Debt Issued | 1.00M | 2.50M | ||||
| Short-Term Debt Repaid | -150.00K | |||||
| Total Debt Repaid | -150.00K | |||||
| Net Debt Issued (Repaid) | 1.00M | 2.35M | ||||
| Issuance of Common Stock | 1.74M | |||||
| Other Financing Activities | 13.96M | 13.96M | 6.41M | 1.17M | -1.63M | |
| Financing Cash Flow | 13.96M | 13.96M | 9.15M | 2.35M | 1.17M | -1.63M |
| Net Cash Flow | 1.31M | 1.31M | 5.40M | -601.09K | -419.16K | -3.06M |
| Free Cash Flow | -8.14M | -8.14M | -3.74M | -2.95M | -1.59M | -1.40M |
| Free Cash Flow Per Share | -14.74 | -14.74 | -121.22 | |||
| Levered Free Cash Flow | -4.96M | -4.96M | -3.39M | -1.71M | -316.33K | |
| Unlevered Free Cash Flow | -4.95M | -4.95M | -3.39M | -1.68M | -316.33K | |
| Change in Working Capital | -1.22M | -1.22M | -386.20K | -1.17M | 1.48M | 129.75K |
Ratios
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 12.63M | 5.64M | 2.72M | 15.26M | 97.26M | 327.04M |
| Enterprise Value | 5.18M | -1.51M | 2.08M | 15.40M | ||
| Last Close Price | 3.31 | 2.46 | 29.89 | 4,258.98 | 39,616.74 | 37,396.84 |
| PE Ratio | 2.69 | |||||
| PB Ratio | 0.45 | 0.33 | 0.40 | -1.39 | -485.22 | 192.34 |
| P/TBV Ratio | 0.75 | 0.33 | 0.40 | 192.34 | ||
| Debt / Equity Ratio | -0.95 | |||||
| Net Debt / Equity Ratio | -0.44 | -0.44 | -0.91 | -0.89 | 6.66 | -1.03 |
| Net Debt / EBITDA Ratio | 1.20 | 1.20 | 1.68 | -3.53 | ||
| Net Debt / FCF Ratio | 0.91 | 0.91 | 1.64 | -3.29 | 0.84 | 1.26 |
| Quick Ratio | 12.12 | 12.12 | 10.55 | 0.06 | 0.83 | 13.62 |
| Current Ratio | 14.62 | 14.62 | 11.04 | 0.09 | 0.89 | 13.90 |
| Return on Equity (ROE) | -58.62% | -58.62% | -468.63% | |||
| Return on Assets (ROA) | -31.33% | -31.33% | -54.20% | -126.35% | -123.25% | |
| Return on Capital Employed (ROCE) | -36.80% | -36.80% | -54.50% | 25.10% | 1,613.80% | -109.20% |
| Earnings Yield | -379.44% | -122.95% | 37.25% | -335.16% | -3.30% | -0.57% |
| FCF Yield | -64.50% | -144.34% | -137.84% | -19.33% | -1.64% | -0.43% |
| Buyback Yield / Dilution | -1,688.07% | -1,688.07% |